COPD exacerbation - Heliox Therapy - AssessmentHeliox vs. Medical Air in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Pilot Randomised Controlled Trial - Pilot CHeTA

BOC Ltd.0 个研究点目标入组 24 人开始时间: 2008年10月17日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Be admitted to ED with a clinical diagnosis of an acute exacerbation of COPD
•(acute onset of a sustained worsening of the patient’s symptoms from their usual
•stable state which is beyond normal day-to-day variations).
•Have a Past Medical History of a diagnosis of COPD
•Age > 40 years.
•After initial nebulisation have two of: RR>30, HR>100, purulent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Have left ventricular failure.
•Unable to give informed consent.
•Clinical anticipation of intubation or non-invasive ventilation before randomisation.
•Have participated in this trial before.
•Participation in any investigational drug study within 4 weeks preceding or during this study period.
•Clinical suspicion of large consolidation.
•Encephalopathic

发起方

BOC Ltd.